Bayer outlined its 2030 growth strategy at Pharma Media Day 2026, driven by AI partnerships, precision medicine, and a strengthened pipeline. The company aims for mid-single-digit growth from 2027 and 30% margins by 2030.
The U.S. cardiovascular drugs market is projected to reach $37.03 billion by 2035, growing at a CAGR of 2.68%. Europe's anticoagulants market is expected to reach $23.68 billion by 2033, expanding at a CAGR of 8.22%.
Scientists have developed a new transcriptomic clock that predicts biological age and mortality using gene activity patterns conserved across species. Longevity experts also recommend tracking specific biomarkers like fasting glucose, ApoB, and hs-CRP with optimal ranges to monitor health proactively. Regular biomarker testing from mid-30s onwards is encouraged for early detection of age-related changes.
Two separate studies examine interventions for individuals affected by preterm birth. A structured exercise program improved cardiovascular health and blood pressure in young adults born preterm. Meanwhile, prophylactic acetaminophen given to extremely preterm infants did not improve survival without severe morbidity, despite accelerating closure of a common heart defect.
Recent studies using FDA Adverse Event Reporting System data have identified drug-associated cardiovascular risks, pediatric dry eye, and venlafaxine adverse effects. Findings highlight the importance of pharmacovigilance monitoring.
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
NewAmsterdam Pharma said regulatory decisions on obicetrapib in Europe, the UK and Switzerland remain expected in 2H26. PREVAIL interim analysis is planned for 4Q2026, with a result expected in 1Q2027.
LIB Therapeutics launched Lerochol in the United States after FDA approval for lowering LDL-C in adults with hypercholesterolemia, including HeFH. The once-monthly PCSK9 inhibitor is available with a $199-per-month cash-pay option.
Research in the United Kingdom found that preventing type 2 diabetes cut care-related greenhouse gas emissions by about 67%, while well-controlled disease was linked to 21% lower emissions than uncontrolled diabetes.
C-peptide is described as a key biomarker for beta cell function in type 1 diabetes and a potential surrogate endpoint for drug approval. Current trial endpoints remain difficult for disease-modifying therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07578090 |
Regional Innovation in Chronic Disease and Elderly Care |
RECRUITING | |
| NCT07521436 |
Awareness of Risk Factors and Perception of Cardiovascular Risk in Secondary Prevention Among Women and Men |
RECRUITING | |
| NCT07518719 |
Feasibility of The Health Integrated Nutrition and Kidney Wellness Program |
RECRUITING | NA |
| NCT07507409 |
Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients |
NOT_YET_RECRUITING | PHASE4 |
| NCT07500948 |
Effectiveness of Pollution Monitoring in Clinical Exercise Rehabilitation |
NOT_YET_RECRUITING | NA |
| NCT07497932 |
Nutritional Effects in Cardiovascular Surgery |
RECRUITING | NA |
| NCT07485283 |
Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia |
RECRUITING | PHASE4 |
| NCT07481825 |
Impact of Combined Cardio-pulmonary Assessment on COPD Clinical Management. |
NOT_YET_RECRUITING | NA |
| NCT07466056 |
Application of Non-inductive Intelligent Physical Sign Monitoring Equipment Based on Flexible Electronic Devices in the Diagnosis and Treatment of Cardiovascular Diseases |
RECRUITING | |
| NCT07431515 |
Long-term Risk of Cardiovascular Disease in Living Kidney Donors |
COMPLETED |
